FAAH and schizophrenia: Despite a growing consensus that the cannabinoids can modulate schizophrenia-like symptoms [16, 17], as well as that there are some findings of indirect modulation in endocannabinoids levels gain with FAAH or MAGL inhibitors on memory or locomotion in rodents [18–22], there is a distinct lack of evidence regarding to the influence of these inhibitors on the specific schizophrenia-like responses in animals.